Intrastriatal grafting of Cos cells stably expressing human aromatic L- amino acid decarboxylase: Neurochemical effects

Journal of Neurochemistry

Volumn 68, Issue 4, 1997, Pages 1520-1526

  Kaddis, Farida G ^a   Clarkson, Edward D ^a   Weber, Michel J ^c   Vandenbergh, David J ^b   Donovan, David M ^b   Mallet, Jacques ^d   Horellou, Philippe ^d   Uhl, George R ^b   Freed, Curt R ^a,e  

^a UNIVERSITY OF COLORADO   (United States)

^b NIDA Addiction Research Center   (United States)

^c CNRS   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

Aromatic L amino acid decarboxylase; Cos cells; L DOPA; Parkinson's disease; Stable expression; Transfected cells; Transplantation

Indexed keywords

AMINO ACID DECARBOXYLASE;

ANIMAL CELL; ARTICLE; BIOTRANSFORMATION; BRAIN GRAFT; CORPUS STRIATUM; DECARBOXYLATION; DRUG EFFECT; ENZYME STABILITY; GENE EXPRESSION REGULATION; NERVE ENDING; NEUROCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM;

ANIMALIA;

EID: 0030893608     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.1997.68041520.x     Document Type: Article

References (46)

1. Albert V. R., Allen J. M., and Joh T. H. (1987) A single gene codes for aromatic L-amino acid decarboxylase in both neuronal and non-neuronal tissues. J. Biol. Chem. 262, 9404-9411.
2. Bertler A., Falck B., Owman C., and Rosengren E. (1966) The localization of monoaminergic blood-brain barrier mechanisms. Pharmacol. Rev. 18, 369-385.
3. Cao L., Zheng Z.-C., Zhao Y.-C., Jiang Z.-H., Lie Z.-G., Chen S.-D., Zhou C.-F., and Liu X.-Y. (1995) Gene therapy of Parkinson disease model rat by direct injection of plasmid DNA-lipofection complex. Hum. Gene Ther. 6, 1497-1501.
4. Cavilli-Sforza L. L., Santachiara S. A., Wang L., Erdelyi E., and Barchas J. (1974) Electrophoretic study of 5-hydroxytryptophan decarboxylase from brain and liver in several species. J. Neurochem. 23, 629-634.
5. Cotzias G. C., Van Woert M. H., and Schiffer I. M. (1967) Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. 276, 374-379.
6. During M. J., Naegele J. R., O'Malley K. L., and Geller A. (1994) Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 266, 1399-1403.
7. Duvoisin R. C. and Mytilineou C. (1978) Where is L-DOPA decarboxylated in the striatum after 6-hydroxydopamine nigrotomy? Brain Res. 152, 369-373.
8. Fisher L. J., Jinnah H. A., Kale L. C., Higgins G. A., and Gage F. H. (1991) Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa. Neuron 6, 371-380.
9. Freed C. R., Breeze R. E., Rosenberg N. L., Schneck S. A., Wells T. H., Barrett J. N., Grafton S. T., Huang S. C., Eidelberg D., and Rottenberg D. A. (1990) Transplantation of human fetal dopamine cells for Parkinson's disease: results at one year. Arch. Neurol. 47, 505-512.
10. Freed C. R., Breeze R. E., Rosenberg N. L., and Schneck S. A. (1992a) Embryonic dopamine cell implants as a treatment for the second phase of Parkinson's disease: replacing failed nerve terminals, in Advances in Neurology, Vol. 60 (Narabayashi H., Nagatsu T., Yanagisawa N., and Mizuno Y., eds), pp. 721-728. Raven Press, New York.
11. Freed C. R., Breeze R. E., Rosenberg N. L., Schneck S. A., Kriek E., Qi J.-X., Lone T., Zhang Y.-B., Snyder J. A., Wells T. H., Ramig L. O., Thompson L., Mazziotta J. C., Huang S. C., Grafton S. T., Brooks D., Sawle G., Schroter G., and Ansari A. A. (1992b) Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N. Engl. J. Med. 327, 1549-1555.
12. Hefti F. and Melamed E. (1980) L-DOPA's mechanism of action in Parkinson's disease. Trends Neurosci. 3, 229-231.
13. Hefti F., Melamed E., and Wurtman R. J. (1981) The site of dopamine formation in rat striatum after L-DOPA administration. J. Pharmacol. Exp. Ther. 217, 189-197.
14. Hökfelt T., Fuxe K., and Goldstein M. (1973) Immunohistochemical localization of aromatic L-amino acid decarboxylase (DOPA decarboxylase) in central dopamine and 5-hydroxytryptamine nerve cell bodies of the rat brain. Brain Res. 53, 175-180.
15. Horellou P., Brundin P., Kalen P., Mallet J., and Bjorklund A. (1990a) In vivo release of DOPA and dopamine from genetically engineered cells grafted to the denervated striatum. Neuron 5, 393-402.
16. Horellou P., Marlier L., Privat A., and Mallet J. (1990b) Behavioral effect of engineered cells that synthesize L-dopa or dopamine after grafting into the rat neostriatum. Eur. J. Neurosci. 2, 116-119.
17. Horellou P., Vigne E., Castel M. N., Barneoud P., Colin P., Perricaudet M., Delaere P., and Mallet J. (1994) Direct intracerebral gene transfer of an adenovirus vector expressing tyrosine hydroxylase in rat model of Parkinson's disease. Neuroreport 6, 49-53.
18. Ichinose H., Kojima K., Togari A., Kato Y., Parvez S., Parvez H., and Nagatsu T. (1985) Simple purification of aromatic L-amino acid decarboxylase from human pheochromocytoma using high-performance liquid chromatography. Anal. Biochem. 150, 408-414.
19. Kang U. J. and Joh T. H. (1990) Deduced amino acid sequence of bovine aromatic L-amino acid decarboxylase: homology to other decarboxylases. Mol. Brain Res. 8, 83-87.
20. Kang U. J., Fisher L. J., Jch T. H., O'Malley K. L., and Gage F. H. (1993) Regulation of dopamine production by genetically modified primary fibroblasts. J. Neurosci. 13, 5203-5211.
21. Karoum F., Freed W. J., Chuang L.-W., Cannon-Spoor E., Wyatt R. J., and Costa E. (1988) D-DOPA and L-DOPA similarly elevate brain dopamine and produce turning behavior in rats. Brain Res. 440, 190-194.
22. Krieger M., Coge F., Gross F., and Thibault J. (1991) Different mRNAs code for DOPA decarboxylase in tissues of neuronal and nonneuronal origin. Proc. Natl. Acad. Sci. USA 88, 2161-2165.
23. Lesser R. P., Fahn S., Snider S. R., Cote L. J., Isgreen W. P., and Barrett R. E. (1979) Analysis of the clinical problem in parkinsonism and the complications of long-term levodopa therapy. Neurology 29, 1253-1260.
24. Le Van Thai A., Costa E., Allen J. M., Palmiter R. D., and Weber M. J. (1993) Identification of neuron-specific promoter of human aromatic L-amino acid decarboxylase gene. Mol. Brain Res. 17, 227-238.
25. Lloyd K. and Hornykiewicz O. (1970) Parkinson's disease: activity of L-DOPA decarboxylase in discrete brain regions. Science 170, 1212-1213.
26. Lloyd K. G., Davidson L., and Hornykiewicz O. (1975) The neurochemistry of Parkinson's disease: effect of L-DOPA therapy. J. Pharmacol. Exp. Ther. 195, 453-464.
27. Marsden C. D. and Jenner P. (1981) L-DOPA's action in Parkinson's disease. Trends Neurosci. 4, 148-150.
28. Marsden C. D. and Parkes J. D. (1977) Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1, 345-349.
29. Melamed E., Hefti F., Liebman A. J., Schlosberg J., and Wurtman R. J. (1980) Serotonergic neurons are not involved in action of L-DOPA in Parkinson's disease. Nature 283, 272-274.
30. Melamed E., Globus M., Friedlander E., and Rosenthal J. (1983) Chronic L-DOPA administration decreases striatal accumulation of dopamine from exogenous L-DOPA in rats with intact nigro-striatal projections. Neurology 33, 950-953.
31. Mouradian M. M. and Chase T. N. (1988) Central mechanisms and levodopa response fluctuations in Parkinson's disease. Clin. Neuropharmacol. 11, 378-385.
32. Mouradian M. M., Juncos J. L., Fabbrini G., Schlegel J., Bartko J. J., and Chase T. N. (1988) Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms. Part II. Ann. Neurol. 24, 372-378.
33. Mura A., Jackson D., Manley M. S., Young S. J., and Groves P. M. (1995) Aromatic L-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous L-DOPA to dopamine. Brain Res. 704, 51-60.
34. Ng L. K. Y., Chase T. N., Colburn R. W., and Kopin I. J. (1972) L-DOPA in parkinsonism: a possible mechanism of action. Neurology 22, 688-696.
35. Nutt J. G. (1990) Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 40, 340-345.
36. Park D. H., Kim K.-H., Choi M.-U., Samanta H., and Joh T. H. (1992) Characterization of bovine aromatic L-amino acid decarboxylase expressed in mouse cell line: comparison with native enzyme. Mol. Brain Res. 16, 232-238.
37. Rinne U. K. (1978) Recent advances in research on parkinsonism. Acta Neurol. Scand. 57, (Suppl. 67) 77-113.
38. Sims K. L., Davis G. A., and Bloom F. E. (1973) Activities of 3,4-dihydroxy-L-phenylalanine and 5-hydroxy-L-tryptophan decarboxylases in rat brain: assay characteristics and distribution. J. Neurochem. 20, 449-464.
39. Sumi C., Ichinose H., and Nagatsu T. (1990) Characterization of recombinant human aromatic L-amino acid decarboxylases expressed in COS cells. J. Neurochem. 55, 1075-1078.
40. Takashima H., Tsujihata M., Niwa M., and Nagataki S. (1987) Effects of chronic administration of L-DOPA and bromocriptine on the dopaminergic metabolism in the rat striatum. Biogen. Amines 4, 15-22.
41. Ungerstedt U. (1971) Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. Suppl. 367, 69-93.
42. 14C-L-tyrosine. Anal. Biochem. 43, 588-600.
43. Wolff J. A., Fisher L. J., Xu L., Jinnah H. A., Langlais P. J., Iuvone P. M., O'Malley K. L., Rosenberg M. B., Shimohama S., Friedmann T., and Gage F. H. (1989) Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease. Proc. Natl. Acad. Sci. USA 86, 9011-9014.
44. Yahr M. D. (1977) Long-term levodopa in Parkinson disease. Lancet 1, 706-707.
45. Zetterström T., Herrera-Marschitz M., and Ungerstedt U. (1986) Simultaneous measurement of dopamine release and rotational behaviour in 6-hydroxydopamine denervated rats by intracerebral dialysis. Brain Res. 376, 1-7.
46. Zhong X.-H., Haycock J. W., Shannak K., Robitaille Y., Fratkin J., Koeppen A., Hornykiewicz O., and Kish S. J. (1995) Striatal dihydroxyphenylalanine decarboxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy. Mov. Disord. 10, 10-17.